搜索
 > 【VEGF-C】重组蛋白信息

VEGF-C信息

英文名称:Vascular endothelial growth factor C
中文名称:血管内皮生长因子C
靶点别称:VEGFC,Flt4-L,Flt4 ligand,VRP,Vascular endothelial growth factor C,Vascular endothelial growth factor-related protein,VEGF-C
上市药物数量:0
临床药物数量:3
最高研发阶段:临床二期

VEGF-C产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
VEC-H4225
Human
Human VEGF-C / Flt4-L Protein, His Tag
 
评论(0)
 

VEGF-C 分子别名

VEGFC,Flt4-L,VRP

VEGF-C 分子背景

Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

VEGF-C 参考文献

VEGF-C临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
VEGF-C gene therapy (Herantis Pharma) Ad-VEGF-C; LX-1101,LX1101; LX 1101 临床二期 Herantis Pharma 继发性淋巴水肿 详情
OPT-302 OPT-302; VGX-300,OPT302; VGX300,OPT 302; VGX 300 临床二期 Orphan Europe 年龄相关性黄斑变性, 糖尿病性黄斑水肿 详情
VGX-100 VGX-100 临床二期 Vegenics, Ceres Oncology, Opthea 实体瘤, 眼部疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定